Sacituzumab Govitecan Moves Into First-Line TNBC Care

The June 24, 2026, decision moves the TROP-2–directed antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) from later-line treatment into two distinct first-line settings for adults with unresectable locally advanced or metastatic triple-negative breast cancer. One indication is monotherapy for patients who are not candidates for PD-1 or PD-L1 inhibitors. The other combines sacituzumab govitecan with pembrolizumab for tumors expressing PD-L1 at a combined positive score of at least 10, as established by an FDA-approved test.

The distinction matters. These are not interchangeable options for all patients with newly diagnosed metastatic disease, and the monotherapy indication is not simply a lower-intensity version of the combination indication. Clinicians must first establish PD-L1 status and then determine whether checkpoint inhibition is clinically appropriate, while accounting for prior perioperative therapy, comorbidities and the different adverse-event profiles of the two regimens.

Two approvals supported by two trials

The combination indication was supported by ASCENT-04, a phase 3 randomized trial enrolling 443 patients with previously untreated, unresectable locally advanced or metastatic triple-negative breast cancer whose tumors had a PD-L1 combined positive score of at least 10. Participants received sacituzumab govitecan plus pembrolizumab or chemotherapy plus pembrolizumab.

The antibody-drug conjugate combination prolonged progression-free survival, the trial’s principal efficacy measure. Median progression-free survival was 11.2 months with sacituzumab govitecan plus pembrolizumab and 7.8 months with chemotherapy plus pembrolizumab. The hazard ratio for progression or death was 0.65, with a 95% confidence interval of 0.51 to 0.84 and a reported P value of 0.0009.

The monotherapy indication rested on ASCENT-03, another phase 3 randomized trial, which enrolled 558 patients with previously untreated, unresectable locally advanced or metastatic triple-negative breast cancer who were not candidates for PD-1 or PD-L1 inhibition. Sacituzumab govitecan was compared with physician’s-choice chemotherapy.

Median progression-free survival was 9.7 months with sacituzumab govitecan and 6.9 months with chemotherapy. The hazard ratio was 0.62, with a 95% confidence interval of 0.50 to 0.77 and P<0.0001.

These comparisons answer different questions. ASCENT-04 tested whether replacing the chemotherapy component of a pembrolizumab-containing regimen with sacituzumab govitecan improved outcomes in PD-L1–positive disease. ASCENT-03 tested sacituzumab govitecan against chemotherapy when checkpoint inhibition was not an option. The hazard ratios therefore should not be used to compare monotherapy directly with the pembrolizumab combination.

How treatment selection changes

PD-L1 testing becomes an early branch point. A combined positive score of at least 10 identifies the population covered by the pembrolizumab combination indication, but a positive result does not by itself establish that immunotherapy is suitable. Active autoimmune disease, solid-organ transplantation, immunosuppressive treatment, prior severe immune-mediated toxicity and other clinical factors may weigh against checkpoint inhibition.

Conversely, the monotherapy indication is tied to being unsuitable for a PD-1 or PD-L1 inhibitor. That language makes the reason for avoiding immunotherapy clinically important. It may reflect tumor biomarker status, a contraindication, unacceptable risk or another documented factor, rather than patient or clinician preference alone.

Prior therapy also complicates the decision. Some patients presenting with metastatic disease will already have received pembrolizumab, chemotherapy or another systemic treatment in the neoadjuvant or adjuvant setting. The applicability of the first-line trial results may depend on what was previously given, the interval to recurrence and whether prior toxicities resolved. Evidence is particularly limited for patients previously exposed to sacituzumab govitecan or another antibody-drug conjugate in early-stage disease.

Other biomarkers still matter. Germline BRCA1 or BRCA2 status may create a role for a PARP inhibitor, while HER2 expression can influence later-line antibody-drug conjugate options even when a tumor meets the definition of triple-negative disease. The new approvals expand the first-line menu; they do not remove the need to plan treatment sequencing across the disease course.

Toxicity and delivery remain central

Sacituzumab govitecan couples a TROP-2–directed antibody with SN-38, a topoisomerase I inhibitor payload. Its established safety concerns include severe neutropenia and diarrhea, both of which appear in boxed warnings, as well as nausea, fatigue, alopecia, anemia and vomiting. Patients with reduced UGT1A1 activity can have increased toxicity risk. Laboratory monitoring, supportive care and the practical burden of an intravenous regimen remain relevant.

Adding pembrolizumab introduces a separate set of immune-mediated risks involving organs such as the lungs, liver, bowel, thyroid and other endocrine glands. Some immune toxicities can be prolonged or irreversible. Selection therefore requires comparing the expected benefit of checkpoint inhibition with both immediate and long-term risks, rather than treating PD-L1 positivity as an automatic instruction to combine the drugs.

The comparator matters when counseling about benefit. In ASCENT-04, both groups received pembrolizumab; the trial isolated the effect of substituting sacituzumab govitecan for conventional chemotherapy within that framework. In ASCENT-03, the control was physician’s-choice chemotherapy. Neither trial established that sacituzumab govitecan is superior to every other biomarker-directed or sequencing strategy that may be relevant to an individual patient.

Important gaps after the approval

Progression-free survival was the central efficacy result supporting both indications. Longer follow-up is needed to clarify overall survival, late toxicity and whether earlier sacituzumab govitecan exposure changes the effectiveness of subsequent therapies. Mature survival data will be especially important because moving an active later-line treatment forward can improve initial disease control without necessarily extending survival if later treatment options are altered.

Generalizability is another limitation. Trial eligibility can underrepresent patients with poor performance status, uncontrolled brain metastases, substantial organ dysfunction, serious autoimmune conditions or limited marrow reserve. These are often the patients for whom the treatment choice is most difficult. Both studies were sponsor-funded, and the concise FDA review announcement cannot substitute for detailed appraisal of complete trial reports, subgroup analyses and updated follow-up.

Cross-trial comparison is inappropriate. The two studies enrolled biologically and clinically different populations, used different control regimens and addressed different therapeutic questions. Their median progression-free survival values do not establish that one approved approach is more effective than the other.

Questions clinicians ask

Does every patient need PD-L1 testing before first-line treatment?

PD-L1 testing is necessary to identify patients covered by the sacituzumab govitecan plus pembrolizumab indication, which requires a combined positive score of at least 10 on an FDA-approved test. Testing should occur early enough to inform treatment, but immunotherapy candidacy still requires a separate clinical assessment.

When does the monotherapy indication apply?

Sacituzumab govitecan monotherapy is approved for adults with unresectable locally advanced or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibition. The reason may involve biomarker status or clinical contraindications, and documenting that rationale can help distinguish this population from patients eligible for pembrolizumab-containing care.

Can the two trial results be compared directly?

No. ASCENT-04 studied sacituzumab govitecan plus pembrolizumab in PD-L1–positive disease, whereas ASCENT-03 evaluated sacituzumab govitecan alone in patients unsuitable for checkpoint inhibition. Different populations and control regimens mean the hazard ratios and median progression-free survival estimates cannot establish superiority of one approved strategy over the other.

What remains uncertain about using sacituzumab govitecan earlier?

Key uncertainties include mature overall survival, long-term toxicity and the best sequence after progression. Evidence is also limited for patients previously treated with pembrolizumab or an antibody-drug conjugate in early-stage disease, as well as those with poor performance status, major organ dysfunction or other characteristics commonly excluded from trials.

References

1. FDA approves sacituzumab govitecan-hziy monotherapy and in combination with pembrolizumab for first-line triple-negative breast cancer indications — U.S. Food and Drug Administration, 2026
2. ASCENT-04: Sacituzumab Govitecan-hziy and Pembrolizumab Versus Chemotherapy and Pembrolizumab in Untreated Advanced Triple-Negative Breast Cancer — ClinicalTrials.gov, 2022
3. ASCENT-03: Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Untreated Advanced Triple-Negative Breast Cancer — ClinicalTrials.gov, 2022